RESUMO
Huntington's Disease (HD) is notable for selective neuronal vulnerability in the basal ganglia and cerebral cortex. We have investigated in human and rodent tissues the expression of the gene (IT15) whose mutation causes HD. IT15 is widely expressed, with highest levels of expression in brain, but also in lung, testis, ovary, and other tissues. Within the brain, expression is widespread with a neuronal pattern and is not enriched in the basal ganglia. Expression of IT15 is not reduced in the brain of HD patients when corrected for actin (though it is slightly decreased in the striatum when uncorrected, consistent with neuronal loss). Thus, the widespread distribution of IT15 expression does not correspond with the restricted distribution of neuropathologic changes in HD. We suggest that pathophysiology may relate to abnormal cell type-specific protein interactions of the HD protein.
Assuntos
Expressão Gênica , Genes , Doença de Huntington/genética , Animais , Sequência de Bases , Northern Blotting , Humanos , Hibridização In Situ , Pessoa de Meia-Idade , Sondas Moleculares/genética , Dados de Sequência Molecular , RNA Mensageiro/metabolismo , Ratos , Ratos Sprague-Dawley , Distribuição TecidualRESUMO
OBJECTIVE: To describe characteristics of gene-negative patients with clinical features of Huntington's disease (HD), exploring likely etiologies. BACKGROUND: When a direct gene test became definitive for diagnosis of HD, we discovered a number of patients in our clinics in Baltimore, MD, and Cambridge, UK, believed or suspected to have HD who did not have the triplet repeat expansion. METHODS: Patients were examined using standardized instruments, and given full neurologic and psychiatric evaluations. Those negative for HD were tested for dentatorubro-pallidoluysian atrophy, SCA-1, SCA-3, SCA-2, SCA-6, and other conditions as indicated. RESULTS: Of 15 patients, 7 received specific diagnoses or appear to be sporadic cases, 4 have a possible but uncertain relation to HD, and 4 have unknown familial progressive movement disorders. CONCLUSIONS: This last group of patients might be properly described as phenocopies of HD, some of which may be caused by unidentified triplet repeat expansions.
Assuntos
Doença de Huntington/genética , Proteínas do Tecido Nervoso/genética , Proteínas Nucleares/genética , Repetições de Trinucleotídeos , Adulto , Química Encefálica , Estudos de Coortes , Saúde da Família , Feminino , Humanos , Proteína Huntingtina , Doença de Huntington/diagnóstico , Imageamento por Ressonância Magnética , Masculino , Mutação , Linhagem , FenótipoRESUMO
The authors review the records of 6 patients with Huntington's disease (HD) who received electroconvulsive therapy (ECT) for depression. Five patients met criteria for major depression and 1 for bipolar disorder, depressed. None of the patients had responded to pharmacologic intervention, and 5 improved after ECT treatment. The 2 patients who had prominent delusions showed the greatest improvement. Apathy, and to some extent irritability, responded less well. One patient developed delirium, and the movement disorder worsened in another patient. ECT should be a treatment option in the management of depression in Huntington's disease, particularly when depression is resistant to pharmacologic treatment.
Assuntos
Transtorno Bipolar/terapia , Transtorno Depressivo/terapia , Eletroconvulsoterapia , Doença de Huntington/terapia , Transtornos Neurocognitivos/terapia , Adulto , Transtorno Bipolar/genética , Transtorno Bipolar/psicologia , Terapia Combinada , Transtorno Depressivo/genética , Transtorno Depressivo/psicologia , Feminino , Seguimentos , Humanos , Doença de Huntington/genética , Doença de Huntington/psicologia , Masculino , Pessoa de Meia-Idade , Transtornos Neurocognitivos/genética , Transtornos Neurocognitivos/psicologiaRESUMO
The authors describe the use of cisapride (Propulsid), a potent 5-HT(3) antagonist, in the treatment of visual hallucinations in two patients with vision loss (the Charles Bonnet syndrome).
Assuntos
Cisaprida/uso terapêutico , Alucinações/tratamento farmacológico , Agonistas do Receptor de Serotonina/uso terapêutico , Baixa Visão/complicações , Idoso , Feminino , Alucinações/etiologia , Humanos , Masculino , Síndrome , Percepção VisualRESUMO
Sertraline, a selective serotonin reuptake inhibitor, was used to treat two consecutive cases of genetically confirmed Huntington's disease in which severe irritability and aggressiveness required inpatient admission. The complete cessation of aggressive behavior in both cases has been maintained on follow-up. This report adds to the literature implicating serotonergic mechanisms in irritability and aggressiveness in both neuropsychiatric and idiopathic psychiatric disorders.
Assuntos
1-Naftilamina/análogos & derivados , Agressão/efeitos dos fármacos , Doença de Huntington/tratamento farmacológico , Doença de Huntington/psicologia , Inibidores Seletivos de Recaptação de Serotonina/uso terapêutico , 1-Naftilamina/uso terapêutico , Adulto , Agressão/psicologia , Feminino , Humanos , Humor Irritável , Masculino , Pessoa de Meia-Idade , SertralinaRESUMO
This paper reviews the various resources available to psychiatrists for keeping abreast of the current literature and research in the field and reports the results of a survey that assesses psychiatrists' current practices in tracking the literature. The respondents' knowledge of available resources, their usual searching practices, and their satisfaction with the resource network are presented. The authors draw conclusions about the most efficient means of tracking the literature for various purposes and offer suggestions about improving resources.
RESUMO
One hundred patients with clinically diagnosed Huntington's disease (HD) were randomized to either idebenone, an antioxidant and enhancer of oxidative metabolism, or placebo, in a 1-year, double-blind, parallel-group study aimed at slowing the rate of progression of the disease. Ninety-one patients completed the study. There were no significant differences between groups on the primary outcome measures of the Huntington's Disease Activities of Daily Living Scale (ADL-an index of functional status) and the Quantified Neurologic Examination (QNE). Sample size calculations based on progression of the ADL and QNE in this study group revealed that a larger study group is necessary to detect any differences less than an almost complete halting of the disease. This argues for multicenter efforts for future therapeutic trials in HD.
Assuntos
Antioxidantes/farmacologia , Antioxidantes/uso terapêutico , Benzoquinonas/farmacologia , Benzoquinonas/uso terapêutico , Doença de Huntington/tratamento farmacológico , Atividades Cotidianas , Adulto , Método Duplo-Cego , Feminino , Humanos , Estudos Longitudinais , Masculino , Pessoa de Meia-Idade , Placebos , Receptores de Glutamato/efeitos dos fármacos , Resultado do Tratamento , Ubiquinona/análogos & derivadosRESUMO
Huntington disease (HD) is an autosomal dominant degenerative disorder caused by an expanded and unstable trinucleotide repeat (CAG)n in a gene (IT-15) on chromosome 4. HD exhibits genetic anticipation--earlier onset in successive generations within a pedigree. From a population-based clinical sample, we ascertained parent-offspring pairs with expanded alleles, to examine the intergenerational behavior of the trinucleotide repeat and its relationship to anticipation. We find that the change in repeat length with paternal transmission is significantly correlated with the change in age at onset between the father and offspring. When expanded triplet repeats of affected parents are separated by median repeat length, we find that the longer paternal and maternal repeats are both more unstable on transmission. However, unlike in paternal transmission, in which longer expanded repeats display greater net expansion than do shorter expanded repeats, in maternal transmission there is no mean change in repeat length for either longer or shorter expanded repeats. We also confirmed the inverse relationship between repeat length and age at onset, the higher frequency of juvenile-onset cases arising from paternal transmission, anticipation as a phenomenon of paternal transmission, and greater expansion of the trinucleotide repeat with paternal transmission. Stepwise multiple regression indicates that, in addition to repeat length of offspring, age at onset of affected parent and sex of affected parent contribute significantly to the variance in age at onset of the offspring. Thus, in addition to triplet repeat length, other factors, which could act as environmental factors, genetic factors, or both, contribute to age at onset. Our data establish that further expansion of paternal repeats within the affected range provides a biological basis of anticipation in HD.
Assuntos
Doença de Huntington/genética , Proteínas/genética , Sequências Repetitivas de Ácido Nucleico , Idade de Início , Sequência de Bases , Família , Feminino , Humanos , Proteína Huntingtina , Masculino , Dados de Sequência Molecular , Proteínas do Tecido Nervoso , Proteínas Nucleares , Linhagem , Reação em Cadeia da PolimeraseRESUMO
Dentatorubral and pallidoluysian atrophy (DRPLA) is an autosomal dominant disorder that clinically overlaps with Huntington's disease (HD) and manifests combinations of chorea, myoclonus, seizures, ataxia, and dementia. DRPLA is caused by a CAG triplet repeat (CTG-B37) expansion coding for polyglutamine on chromosome 12 and exhibits the genetic phenomenon of anticipation. This neurodegenerative disease has only rarely been reported in non-Japanese pedigrees, and there are only a few neuropathological studies in genetically confirmed patients. We report 10 cases of DRPLA from two North American and two British pedigrees in which CTG-B37 expansions have been demonstrated within each kindred (54-83 repeats), individually in 8 of the 10 cases, and describe the neuropathological findings in 4 cases. Members of DRPLA kindreds have a wide range of clinical phenotypes and markedly variable ages at onset. The neuropathological spectrum is centered around the cerebellifugal and pallidofugal systems, but neurodegenerative changes can be found in many nuclei, tracts, and systems. Evidence of CTG-B37 triplet repeat expansion should be sought in HD-like cases that are negative for expanded triplet repeats within the HD IT15 gene or in autopsy cases with degeneration of the dentatorubral or pallidoluysian systems.
Assuntos
Encefalopatias/genética , Encéfalo/patologia , Transtornos dos Movimentos/genética , Adulto , Atrofia , População Negra/genética , Encéfalo/fisiopatologia , Encefalopatias/diagnóstico , Encefalopatias/etnologia , Encefalopatias/fisiopatologia , Criança , Cromossomos Humanos Par 12/genética , Giro Denteado/patologia , Diagnóstico Diferencial , Feminino , Globo Pálido/patologia , Humanos , Lactente , Masculino , Pessoa de Meia-Idade , Transtornos dos Movimentos/diagnóstico , Transtornos dos Movimentos/etnologia , Transtornos dos Movimentos/fisiopatologia , Degeneração Neural/genética , Linhagem , Fenótipo , Núcleo Rubro/patologia , Repetições de Trinucleotídeos , Reino Unido , Estados Unidos , População Branca/genéticaRESUMO
The two most consistent features of the diseases caused by trinucleotide repeat expansion-neuropsychiatric symptoms and the phenomenon of genetic anticipation-may be present in forms of dementia, hereditary ataxia, Parkinsonism, bipolar affective disorder, schizophrenia and autism. To identify candidate genes for these disorders, we have screened human brain cDNA libraries for the presence of gene fragments containing polymorphic trinucleotide repeats. Here we report the cDNA cloning of CAGR1, originally detected in a retinal cDNA library. The 2743 bp cDNA contains a 1077 bp open reading frame encoding 359 amino acids. This amino acid sequence is homologous (56% amino acid identify and 81% amino acid conservation) to the Caenorhabditis elegans cell fate-determining protein mab-21. CAGR1 is expressed in several human tissues, most prominently in the cerebellum, as a message of approximately 3.0 kb. The gene was mapped to 13q13, just telomeric to D13S220. A 5'-untranslated CAG trinucleotide repeat is highly polymorphic, with repeat length ranging from six to 31 triplets and a heterozygosity of 87-88% in 684 chromosomes from several human populations. One allele from an individual with an atypical movement disorder and bipolar affective disorder type II contains 46 triplets, 15 triplets longer than any other allele detected. Though insufficient data are available to link the long repeat to this clinical phenotype, an expansion mutation of the CAGR1 repeat can be considered a candidate for the etiology of disorders with anticipation or developmental abnormalities, and particularly any such disorders linked to chromosome 13.
Assuntos
Encefalopatias/genética , Proteínas de Caenorhabditis elegans , Proteínas de Helminto/genética , Proteínas de Homeodomínio , Polimorfismo Genético , Proteínas/genética , Repetições de Trinucleotídeos , Sequência de Aminoácidos , Animais , Sequência de Bases , Northern Blotting , Caenorhabditis elegans/genética , Mapeamento Cromossômico , Cromossomos Humanos Par 13 , Clonagem Molecular , DNA Complementar , Humanos , Dados de Sequência Molecular , Homologia de Sequência de Aminoácidos , Homologia de Sequência do Ácido NucleicoRESUMO
Abnormal CAG expansions in the IT-15 gene are associated with Huntington disease (HD). In the diagnostic setting it is necessary to define the limits of the CAG size ranges on normal and HD-associated chromosomes. Most large analyses that defined the limits of the normal and pathological size ranges employed PCR assays, which included the CAG repeats and a CCG repeat tract that was thought to be invariant. Many of these experiments found an overlap between the normal and disease size ranges. Subsequent findings that the CCG repeats vary by 8 trinucleotide lengths suggested that the limits of the normal and disease size ranges should be reevaluated with assays that exclude the CCG polymorphism. Since patients with between 30 and 40 repeats are rare, a consortium was assembled to collect such individuals. All 178 samples were reanalyzed in Cambridge by using assays specific for the CAG repeats. We have optimized methods for reliable sizing of CAG repeats and show cases that demonstrate the dangers of using PCR assays that include both the CAG and CCG polymorphisms. Seven HD patients had 36 repeats, which confirms that this allele is associated with disease. Individuals without apparent symptoms or signs of HD were found at 36 repeats (aged 74, 78, 79, and 87 years), 37 repeats (aged 69 years), 38 repeats (aged 69 and 90 years), and 39 repeats (aged 67, 90, and 95 years). The detailed case histories of an exceptional case from this series will be presented: a 95-year-old man with 39 repeats who did not have classical features of HD. The apparently healthy survival into old age of some individuals with 36-39 repeats suggests that the HD mutation may not always be fully penetrant.